19.18

3.67% -0.73

Relay Therapeutics Inc (RLAY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RLAY? Forum Prognose

Schlusskurs vom Vortag:

$19.91

Offen:

$19.95

24-Stunden-Volumen:

2.30M

Relative Volume:

0.57

Marktkapitalisierung:

$4.18B

Einnahmen:

$10.68M

Nettoeinkommen (Verlust:

$-272.71M

KGV:

-12.26

EPS:

-1.565

Netto-Cashflow:

$-213.38M

1W Leistung:

+2.40%

1M Leistung:

+20.78%

6M Leistung:

+158.84%

1J Leistung:

+448.00%

1-Tages-Spanne:

$19.15

$20.39

1-Wochen-Bereich:

$18.40

$20.39

52-Wochen-Spanne:

$3.025

$20.79

Relay Therapeutics Inc Stock (RLAY) Company Profile

Firmenname

Relay Therapeutics Inc

Sektor

Healthcare (1089)

Branche

Biotechnology (603)

Telefon

617-370-8837

Adresse

60 HAMPSHIRE STREET, CAMBRIDGE

Mitarbeiter

192

Twitter

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLAY Relay Therapeutics Inc	19.18	4.18B	10.68M	-272.71M	-213.38M	-1.565
VRTX Vertex Pharmaceuticals Inc	480.50	121.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.15	70.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.19	52.94B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.39	38.35B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	272.67	36.40B	4.29B	577.22M	641.34M	4.2086

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-26	Hochstufung	Oppenheimer	Perform → Outperform
2025-12-12	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-04-17	Eingeleitet	Wells Fargo	Equal Weight
2024-09-10	Fortgesetzt	Goldman	Buy
2024-09-10	Hochstufung	Jefferies	Hold → Buy
2024-09-10	Herabstufung	Oppenheimer	Outperform → Perform
2024-05-10	Hochstufung	Barclays	Equal Weight → Overweight
2023-04-20	Hochstufung	Jefferies	Underperform → Hold
2023-04-19	Hochstufung	Raymond James	Outperform → Strong Buy
2023-04-13	Eingeleitet	Raymond James	Outperform
2023-02-03	Eingeleitet	Oppenheimer	Outperform
2022-09-30	Eingeleitet	Barclays	Equal Weight
2022-09-02	Eingeleitet	Stifel	Buy
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-02-01	Eingeleitet	Berenberg	Buy
2021-07-21	Eingeleitet	BofA Securities	Buy
2020-12-15	Bestätigt	H.C. Wainwright	Buy
2020-12-08	Eingeleitet	JMP Securities	Mkt Outperform
2020-11-05	Eingeleitet	H.C. Wainwright	Buy
2020-08-10	Eingeleitet	Cowen	Outperform
2020-08-10	Eingeleitet	Goldman	Buy
2020-08-10	Eingeleitet	Guggenheim	Buy
2020-08-10	Eingeleitet	JP Morgan	Neutral

Alle ansehen

Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten

Jul 19, 2026

Certain Stock Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com

Jul 19, 2026

Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com

Jul 19, 2026

Jul 16, 2026

Why Is RLAY Stock Rising Today? - Stocktwits

Jul 16, 2026

Relay Therapeutics (RLAY) Edges Higher as Stock Tests Key Resistance at $20.68High Volume Stocks - dars.gov.et

Jul 16, 2026

Canaccord initiates Relay Therapeutics stock with buy rating - Investing.com

Jul 16, 2026

Canaccord initiates Relay Therapeutics stock with buy rating By Investing.com - Investing.com UK

Jul 16, 2026

RLAY Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus

Jul 16, 2026

CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29 - Moomoo

Jul 16, 2026

Jul 14, 2026

RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits

Jul 14, 2026

Jul 11, 2026